Cellular basis for therapeutic choices in heart failure.
Opie
Lionel H
LH
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000450:Aldosterone / Q000502:physiology; D000804:Angiotensin II / Q000502:physiology; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005355:Fibrosis; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D009206:Myocardium / Q000473:pathology; D011943:Receptors, Adrenergic, beta / Q000378:metabolism; D015398:Signal Transduction; D020257:Ventricular Remodeling
D000319:Adrenergic beta-Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D011943:Receptors, Adrenergic, beta; D000804:Angiotensin II; D000450:Aldosterone